The study compared the response to neoadjuvant chemotherapy and overall survival in patients with invasive intraductal papillary mucinous neoplasm (i-ipmn) and de novo pancreatic ductal adenocarcinoma (pdac). The results showed that i-ipmn histology was independently associated with a lower risk of recurrence and death. Pathological, radiological, and positron emission tomography responses to neoadjuvant therapy were comparable between i-ipmn and pdac. Furthermore, i-ipmn patients had a significantly higher overall survival and disease-free survival compared to pdac patients. Neoadjuvant chemotherapy can be considered as a treatment option for selected i-ipmn patients.
Journal Article by Fogliati A, Zironda A (…) Truty MJ et 10 al. in Ann Surg Oncol
© 2024. The Author(s).